CTO Centro De Tratamento Oncologico LTDA

The trials here

What the 2 trials at this site are about, from their registry records.

Conditions

• Lung cancer1 trial
• Melanoma1 trial

Phase

• Phase 21 trial
• Phase 31 trial

Status

• Active, not recruiting1 trial
• Completed1 trial

Lead sponsor

• Amgen1 trial
• Janssen Research & Development, LLC1 trial

Running trials

• Active, not recruiting

  Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

  NCT06120140· Phase 2· Janssen Research & Development, LLC· Source

Closed trials

• Completed

  A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

  NCT05907122· Phase 3· Amgen· Source